A prospective open-label study to evaluate the effects of the oral contraceptive Harmonet® (gestodene75/EE20) on body fat
- 31 July 2004
- journal article
- Published by Elsevier in Contraception
- Vol. 70 (1), 65-71
- https://doi.org/10.1016/j.contraception.2003.10.016
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Efficacy, cycle control, and side effects of low- and lower-dose oral contraceptives: a randomized trial of 20 μg and 35 μg estrogen preparationsContraception, 1999
- Oral contraceptive discontinuation: A prospective evaluation of frequency and reasonsAmerican Journal of Obstetrics and Gynecology, 1998
- Oral contraceptive practice guidelinesContraception, 1998
- Investigation of the influence of two low-dose monophasic oral contraceptives containing 20 μg ethinylestradiol/75 μg gestodene and 30 μg ethinylestradiol/75 μg gestodene, on lipid metabolism in an open randomized trialContraception, 1996
- Attitudes to current oral contraceptive use and future developments: The women's perspectiveThe European Journal of Contraception & Reproductive Health Care, 1996
- A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 μg ethinylestradiol/75 μg gestodene and 20 μg ethinylestradiol/150 μg desogestrel, with respect to efficacy, cycle control and toleranceContraception, 1995
- Climacteric symptoms and control of the cycle in women aged 35 years or older taking an oral contraceptive with 0.150 mg desogestrel and 0.020 mg ethinylestradiolContraception, 1995
- Clinical aspects of three new progestogens: Desogestrel, gestodene, and norgestimateAmerican Journal of Obstetrics and Gynecology, 1989
- A new low-dose estrogen oral contraceptive combination: Effect on endocrine parameters and lipid statusContraception, 1987
- Effect of low-dose progestogen-estrogen combination (WL-20) on the menstrual cycle of sexually active women of childbearing ageContraception, 1974